AVANIR Pharma Offers Three Presentations for AVP-825 for Acute Treatment of Migraine

Avanir Pharmaceuticals, Inc.

today announced that data related to the safety and efficacy of AVP-825, a Breath-Powered™ Nasal Delivery of Powdered Sumatriptan for the acute treatment of migraine, will be presented at the American Headache Society's 56^th Annual Scientific Meeting. AVP-825 is an investigational drug-device combination product consisting of low-dose sumatriptan powder delivered intranasally utilizing a novel Breath-Powered™ delivery technology. Avanir Pharmaceuticals, Inc. American Headache Society, 56^th Annual Scientific Meeting, June 26 – 29, 2014, Los Angeles o A Randomized, Double-Blind, Double-Dummy, Active-Comparator Crossover Study of Breath-Powered Nasal Delivery of Sumatriptan Powder (AVP-825) in the Treatment of Acute Migraine (The COMPASS Study) o Session: LBP-37 - Poster Session II o Time: June 28 at 12:30 p.m. PDT o Breath-Powered Nasal Delivery of Powdered Sumatriptan (AVP-825): Migraine Disability and Functional Outcome in a Phase 3 Study (TARGET) o Session: P42 - Poster Session I o Time: June 27 at 1:00 p.m. PDT o Breath-Powered Nasal Delivery of Sumatriptan Powder (AVP-825): An Exploratory Analysis of Response in Migraine  Patients Grouped by Baseline Headache Intensity from the Phase 3 TARGET Study o Session: P43 - Poster Session II o Time: June 28 at 12:30 p.m. PDT